- MDPHP
- 3′,4′-Methylenedioxy-α-(pyrrolidin-1-yl)hexanophenone
- 3,4-MDPHP
- MDPHeP
Kaizaki-Mitsumoto, A; Noguchi, N; Yamaguchi, S; Odanaka, Y; Matsubayashi, S; Kumamoto, H; Fukuhara, K; Funada, M; Wada, K; Numazawa, S. Three 25-NBOMe-type drugs, three other phenethylamine-type drugs (25I-NBMD, RH34, and escaline), eight cathinone derivatives, and a phencyclidine analog MMXE, newly identified in ingredients of drug products before they were sold on the drug market Forensic Toxicol., 1 Jan 2016, 34 (1), 108–114. 854 kB. https://doi.org/10.1007/s11419-015-0293-6 #8 MS,NMR
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2015. 879 kB.
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature Forensic Sci. Int., 1 May 2019, 298, 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #MDPHP
Sasaki, R; Kato, M; Matsumoto, T; Udagawa, A; Matsuzaki, R. A method for identifying designer drugs of synthetic cathinones JCCL, 1 Dec 2015, (55), 17–41. 663 kB. #25 Japanese, English abstract MS,NMR,IR,UV
Chen, Y; Canal, CE. Structure–activity relationship study of psychostimulant synthetic cathinones reveals nanomolar antagonist potency of α-pyrrolidinohexiophenone at human muscarinic M2 receptors ACS Chem. Neurosci., 18 Mar 2020, 11 (6), 960–968. 1.2 MB. https://doi.org/10.1021/acschemneuro.0c00008 #MDPHP